Pharma Biotech Company Valuation an Introduction

Pharma Biotech Company Valuation An Introduction-PDF Download

  • Date:14 Sep 2020
  • Views:0
  • Downloads:0
  • Pages:29
  • Size:750.61 KB

Share Pdf : Pharma Biotech Company Valuation An Introduction

Download and Preview : Pharma Biotech Company Valuation An Introduction


Report CopyRight/DMCA Form For : Pharma Biotech Company Valuation An Introduction


Transcription:

www venturevaluation com,Company Valuation,Product Valuation. OVERVIEW rNPV PRODUCT VALUATION COMPANY VALUATION DEAL STRUCTURING STRATEGIC IMPLICATIONS CASE STUDY 2. www venturevaluation com,Venture Valuation,Mission Independent assessment and valuation of. technology driven companies products in,growth industries. Life Sciences Database Biotechgate com,With Company profiles licensing opportunites. investors and licensing deal information,Experts Finance Biotech Pharma.
Not a venture capitalist,International experience,Track record of over 350 valued companies. Clients such as NVF Fraunhofer Gesellschaft European. Investment Bank VCs Arpida Evolva,www venturevaluation com. Why Valuation,Value implies the inherent worth of a. specific thing,Price depending on the market supply. demand whatever somebody is prepared,Price is what you pay Value is what you get.
By Warren Buffett,Provide basis for negotiation investment. decision fair share price,www venturevaluation com. Why Valuation,Value before investment pre,money value EUR 1 5 m. Investment EUR 0 5 m,Value after investment,post money value 0 5 m. EUR 2 0 m 25,Share Investor,0 5 m 2 m 25 1 5 m,Pre money value.
Investment,www venturevaluation com,Why Valuation,Out licensing of a phase II product. Deal terms up front CHF 1 m,milestones CHF 20 m,royalties 7. rNPV of product,rNPV of deal,rNPV of product CHF 30 m. rNPV of deal CHF 10 m,Split Biotech Pharma 33 66,rNPV risk adjusted net present value. www venturevaluation com,Biotech Valuation,Valuation is key issue in development.
Industry lacks transparency private,Very difficult high uncertainties. High potential for investors,Long investment cycle. Traditional valuation methods unsuited,Complex technology and IP situations. www venturevaluation com,Trends in Valuation,Pharma companies have gap in pipeline. Biotechs do not have resources for late stage,development and distribution.
Licensing model Biotech Pharma,Biotech compete with Pharma in house R D. Pharma compete with investors,Licensing M A IPO,www venturevaluation com. Mind set of Investors,Take high risk but expect high returns. Pressure from investors,Compete in capital market,Probability of failure Return. Government Bond 0 3,Blue Chip Company 10 9,Internet company Nasdaq 50 20.
Biotechnology Company 80 50,www venturevaluation com. Risk as a major factor,1 How can we capture risk,Assessment of the company. 2 How can risk be quantified,rating of factors,www venturevaluation com. Assessment,1 Understand the fundamentals,2 Assumptions drive the valuation. Assessment assumptions are key,Assessment Company Product.
1 Management,3 Technology,www venturevaluation com. Management,1 Completeness skills,2 Track record experience. 3 Motivation Incentive structure,4 Organization,5 Emotional intelligence social. competence,6 Composition and involvement of,1 2 3 4 5 6. insufficent sufficent good high,very poor poor,www venturevaluation com.
Market Environment,Industry Structure Five forces by Michael Porter. 1 Threat of new Entry,2 Rivalry among existing competitors. 3 Pressure from substitute products,4 Dependencies on customers. 5 Dependencies on suppliers,6 Current and future market potential. 7 Customers,8 Political legal dependencies,9 Cost and Sales estimations.
1 2 3 4 5 6,insufficent sufficent good high,very poor poor. www venturevaluation com,Science Technology,1 Intellectual Property IP. 2 Unique selling proposition,3 Alliances partnerships. 4 Management of future,discoveries,5 Time to market. 1 2 3 4 5 6,insufficent sufficent good high,very poor poor.
www venturevaluation com,Assessment to Valuation,Assessment Define risk. 1 2 3 4 5 6,insufficent sufficent good high,very poor poor. Discount rate a Discount rate,b Success rate,Non therapeutic company Therapeutic product. Technology platform company,DCF Discounted Cash Flow. Pharma Biotech Company Valuation an Introduction Dr Patrik Frei May 2015 Palermo Fit for Health 2 0 www venturevaluation com 2 Company Valuation Break Product Valuation OVERVIEW rNPV PRODUCT VALUATION COMPANY VALUATION DEAL STRUCTURING STRATEGIC IMPLICATIONS CASE STUDY Overview www venturevaluation com Mission Experts Finance Biotech Pharma Not a venture

Related Books